Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples

  • Jordan Devereaux
  • Skylar J. Ferrara
  • Thomas S. Scanlan
Part of the Methods in Molecular Biology book series (MIMB, volume 1801)


Thyroid hormone is a principal regulator of essential processes in vertebrate physiology and homeostasis. Synthetic derivatives of thyroid hormone, known as thyromimetics, display desirable therapeutic properties. Thoroughly understanding how thyromimetics distribute throughout the body is crucial for their development and this requires appropriate bioanalytical techniques to quantify drug levels in different tissues. Here, we describe a detailed protocol for the quantification of the thyromimetic sobetirome using liquid chromatography tandem-mass spectrometry (LC-MS/MS).

Key words

Sobetirome Thyromimetic Thyroid hormone LC-MS/MS Drug quantification Pharmacokinetics PK-ADME 


  1. 1.
    Weinberger C, Thompson CC, Ong ES, Lebo R, Gruol DJ, Evans RM (1986) The c-erb-A gene encodes a thyroid hormone receptor. Nature 324:641–646CrossRefPubMedGoogle Scholar
  2. 2.
    Sap J, Munoz A, Damm K, Goldberg Y, Ghysdael J, Leutz A, Beug H, Vennström B (1986) The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 324:635–640CrossRefPubMedGoogle Scholar
  3. 3.
    Thompson CC, Weinberger C, Lebo R, Evans RM (1987) Identification of a novel thyroid hormone receptor expressed in the mammalian central nervous system. Science 237:1610–1614CrossRefPubMedGoogle Scholar
  4. 4.
    Schueler PA, Schwartz HL, Strait KA, Mariash CN, Oppenheimer JH (1990) Binding of 3,5,3′-triiodothyronine (T3) and its analogs to the invitrotranslational products of c-erbA protooncogenes: differences in the affinity of the α- and β -forms for the acetic acid analog and failure of the human testis and kidney α-2 products to bind T3. Mol Endocrinol 4:227–234CrossRefPubMedGoogle Scholar
  5. 5.
    Macchia E, Nakai A, Janiga A, Sakurai A (1990) Characterization of site-specific polyclonal antibodies to c-erbA peptides recognizing human thyroid hormone receptors {alpha}1, {alpha}2, and {beta} and native 3, 5, 3’-triiodothyronine receptor, and study of tissue distribution of the antigen. Endocrinology 126(6):3232–3239CrossRefPubMedGoogle Scholar
  6. 6.
    Lazar MA (1993) Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 14:184–193PubMedPubMedCentralGoogle Scholar
  7. 7.
    Apriletti JW, Baxter JD, Lau K (1995) Expression of the rat α1 thyroid hormone receptor ligand binding domain in Escherichia coli and the use of a ligand-induced conformation change as a method for its purificiation to homogeneity. Protein Expr PurifCrossRefPubMedGoogle Scholar
  8. 8.
    Lin K-H, Fukuda T, Cheng SY (1990) Hormone and DNA binding activity of a purified human thyroid hormone nuclear receptor expressed in Escherichia coli. J Biol Chem 265:5161–5165PubMedGoogle Scholar
  9. 9.
    Ball EH, Shephard LB, Gill GN (1995) Purification and properties of thyroid hormone receptor beta 1 expressed in Escherichia coli as a fusion protein. Protein Expr Purif 6:33–38CrossRefPubMedGoogle Scholar
  10. 10.
    Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ (1995) A structural role for hormone in the thyroid hormone receptor. Nature 378:690–697CrossRefPubMedGoogle Scholar
  11. 11.
    Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR (1998) Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12:3343–3356CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ribeiro RCJ, Apriletti JW, Wagner RL, Feng W, Kushner PJ, Nilsson S, Scanlan TS, West BL, Fletterick RJ, Baxter JD (1998) X-ray crystallographic and functional studies of thyroid hormone receptor. J Steroid Biochem Mol Biol 65:133–141CrossRefPubMedGoogle Scholar
  13. 13.
    Bleicher L, Aparicio R, Nunes FM, Martínez L, Gomes Dias SM, Figueira ACM, Santos MAM, Venturelli WH, da Silva R, Donate PM, Neves FA, Simeoni LA, Baxter JD, Webb P, Skaf MS, Polikarpov I (2008) Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms. BMC Struct Biol 8:8CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Evans RM, Birnberg NC (1982) Glucocorticoid and thyroid hormones transcriptionally regulate growth hormone gene expression. Proc Natl Acad Sci U S A 79:7659–7663CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Larsen PR, Harney JW, Moore DD (1986) Sequences required for cell-type specific thyroid hormone regulation of rat growth hormone promoter activity. J Biol Chem 261:14373–14376PubMedGoogle Scholar
  16. 16.
    Wight PA, Crew MD, Spindler SR (1987) Discrete positive and negative thyroid hormone-responsive transcription regulatory elements of the rat growth hormone gene. J Biol Chem 262:5659–5663PubMedGoogle Scholar
  17. 17.
    Glass CK, Franco R, Weinberger C, Albert VR, Evans RM, Rosenfeld MG (1987) A c-erb-A binding site in rat growth hormone gene mediates trans-activation by thyroid hormone. Nature 329:738–741CrossRefPubMedGoogle Scholar
  18. 18.
    Thompson CC, Evans RM (1989) Trans-activation by thyroid hormone receptors: functional parallels with steroid hormone receptors. Proc Natl Acad Sci U S A 86:3494–3498CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Evans RM, Weinberger CA (1991) Hollenberg, Hormone receptor-related bioassays. SM US Patent OfficeGoogle Scholar
  20. 20.
    Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RCJ, Scanlan TS (1998) A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. Chem Biol 5:299–306CrossRefPubMedGoogle Scholar
  21. 21.
    Yokoyama N, Walker GN, Main AJ (1995) Synthesis and structure-activity relationships of oxamic acid and acetic acid derivatives related to Lthyronine. J Med Chem 38(4):695–707CrossRefPubMedGoogle Scholar
  22. 22.
    Furlow JD, Yang HY, Hsu M, Lim W, Ermio DJ, Chiellini G, Scanlan TS (2004) Induction of larval tissue resorption in Xenopus laevis tadpoles by the thyroid hormone receptor agonist GC-1. J Biol Chem 279:26555–26562CrossRefPubMedGoogle Scholar
  23. 23.
    Trost SU, Swanson E, Gloss B, Wang-Iverson DB, Zhang H, Volodarsky T, Grover GJ, Baxter JD, Chiellini G, Scanlan TS, Dillmann WH (2000) The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 141:3057–3064CrossRefPubMedGoogle Scholar
  24. 24.
    Grover GJ, Egan DM, Sleph PG, Beehler BC, Chiellini G, Nguyen N-H, Baxter JD, Scanlan TS (2004) Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3’-triiodo-l-thyronine. Endocrinology 145:1656–1661CrossRefPubMedGoogle Scholar
  25. 25.
    Scanlan TS, Hartley M, Placzek AT, Righi M (2014) Use of sobetirome in the treatment of x-linked adrenoleukodystrophy. World Intell Prop Org 6, WO 2014/178892 A1Google Scholar
  26. 26.
    Scanlan TS (2010) Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev 15(2):177–182CrossRefPubMedGoogle Scholar
  27. 27.
    Yoshihara HAI, Apriletti JW, Baxter JD, Scanlan TS (2003) Structural determinants of selective thyromimetics. J Med Chem 46:3152–3161CrossRefPubMedGoogle Scholar
  28. 28.
    Borngraeber S, Budny M-J, Chiellini G, Cunha Lima ST, Togashi M, Webb P, Baxter JD, Scanlan TS, Fletterick RJ (2003) Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci U S A 100:15358–15363CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Wagner RL, Huber BR, Shiau AK, Kelly A, Cunha Lima ST, Scanlan TS, Apriletti JW, Baxter JD, West BL, Fletterick RJ (2001) Hormone selectivity in thyroid hormone receptors. Mol Endocrinol 15:398–410CrossRefPubMedGoogle Scholar
  30. 30.
    Ye L, Li Y, Mellström K, Mellin C, Bladh L-G, Koehler K, Garg N, Collazo A, Litten C, Husman B (2003) Thyroid receptor ligands 1 Agonist ligands selective for the thyroid receptor β 1. J Med Chem 46:1580–1588CrossRefPubMedGoogle Scholar
  31. 31.
    Karo Bio AB (1999) Thyroid receptor ligands and method II. US Patent Office December 23Google Scholar
  32. 32.
    Karo Bio AB (2000) Thyroid receptor ligands and method. US Patent Office March 20Google Scholar
  33. 33.
    Grover GJ, Mellström K, Ye L, Malm J, Li Y-L, Bladh L-G, Sleph PG, Smith MA, George R, Vennström B, Mookhtiar K, Horvath R, Speelman J, Egan D, Baxter JD (2003) Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci U S A 100:10067–10072CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Hangeland JJ, Doweyko AM, Dejneka T, Friends TJ, Devasthale P, Mellström K, Sandberg J, Grynfarb M, Sack JS, Einspahr H, Färnegårdh M, Husman B, Ljunggren J, Koehler K, Sheppard C, Malm J, Ryono DE (2004) Thyroid receptor ligands Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta. Bioorg Med Chem Lett 14:3549–3553CrossRefPubMedGoogle Scholar
  35. 35.
    Garg N, Li Y-L, Garcia Collazo AM, Litten C, Ryono DE, Zhang M, Caringal Y, Brigance RP, Meng W, Washburn WN, Agback P, Mellström K, Rehnmark S, Rahimi-Ghadim M, Norin T, Grynfarb M, Sandberg J, Grover G, Malm J (2007) Thyroid receptor ligands Part 8: Thyromimetics derived from N-acylated-alpha-amino acid derivatives displaying modulated pharmacological selectivity compared with KB-141. Bioorg Med Chem Lett 17:4131–4134CrossRefPubMedGoogle Scholar
  36. 36.
    Li Y, Litten C, Koehler K, Mellstrom K (2006) Thyroid receptor ligands Part 4: 4’-amido bioisosteric ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem 16(4):884–886CrossRefGoogle Scholar
  37. 37.
    Hangeland JJ, Friends TJ, Doweyko AM, Mellström K, Sandberg J, Grynfarb M, Ryono DE (2005) A new class of high affinity thyromimetics containing a phenyl-naphthylene core. Bioorg Med Chem Lett 15:4579–4584CrossRefPubMedGoogle Scholar
  38. 38.
    Collazo A-MG, Koehler K, Garg N, Färnegårdh M, Husman B, Ye L, Ljunggren J, Mellström K, Sandberg J, Grynfarb M (2006) Thyroid receptor ligands Part 5: Novel bicyclic agonist ligands selective for the thyroid hormone receptor [beta]. Bioorg Med Chem Lett 16:1240–1244CrossRefGoogle Scholar
  39. 39.
    Friends TJ, Ryono DE, Zhang M (2004) Aniline-derived ligands for the thyroid receptor. US Patent OfficeGoogle Scholar
  40. 40.
    Shiohara H, Nakamura T, Kikuchi N, Ozawa T, Nagano R, Matsuzawa A, Ohnota H, Miyamoto T, Ichikawa K, Hashizume K (2012) Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TRβ ) agonists for the treatment of dyslipidemia. Bioorg Med Chem 20:3622–3634CrossRefPubMedGoogle Scholar
  41. 41.
    Angelin B, Kristensen JD, Eriksson M, Carlsson B, Klein I, Olsson AG, Chester Ridgway E, Ladenson PW (2015) Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J Intern Med 277:331–342CrossRefPubMedGoogle Scholar
  42. 42.
    Berkenstam A, Kristensen J, Mellström K, Carlsson B, Malm J, Rehnmark S, Garg N, Andersson CM, Rudling M, Sjöberg F, Angelin B, Baxter JD (2008) The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci U S A 105:663–667CrossRefPubMedGoogle Scholar
  43. 43.
    Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B (2010) Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 362:906–916CrossRefPubMedGoogle Scholar
  44. 44.
    Sweetlove M (2012) Phase III trial of eprotirome. Pharm Med 26:185–187CrossRefGoogle Scholar
  45. 45.
    Metabasis Therapeutics, Inc. (2004) Phosphorus-containing thyromimetics. US Patent Office. November 16, 2004Google Scholar
  46. 46.
    Boyer SH, Jiang H, Jacintho JD, Reddy MV, Li H, Li W, Godwin JL, Schulz WG, Cable EE, Hou J, Wu R, Fujitaki JM, Hecker SJ, Erion MD (2008) Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 51:7075–7093CrossRefPubMedGoogle Scholar
  47. 47.
    Erion M, Cable E, Ito B (2007) Targeting thyroid hormone receptor-β agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci U S A 104(39):15490–15495CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Taub R, Grimsby J, Larigan JD, Pietranico S, Dvorozniak M, Conde-Knape K (2009) VIA-3196, a liver-directed thyroid beta agonist for treating cardiometabolic disease. Circulation 120:S1095Google Scholar
  49. 49.
    Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes N-E, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang K-S, So S-S, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J (2014) Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor β agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 57:3912–3923CrossRefPubMedGoogle Scholar
  50. 50.
    Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin M-C, Tardif J-C (2013) Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist. Atherosclerosis 230:373–380CrossRefPubMedGoogle Scholar
  51. 51.
    Hester DK II, Duguid RJ, Kelly MJ, Chasnoff A, Dong G, Crow EL, Taub R, Reynolds CH, Choi DS, Wang P (2015), Method of synthesizing thyroid hormone analogs and polymorphs thereof, US Patent Office July 23, 2015Google Scholar
  52. 52.
    Hartley MD, Kirkemo LL, Banerji T, Scanlan TS (2017) A thyroid hormone–based strategy for correcting the biochemical abnormality in XLinked adrenoleukodystrophy. Endocrinology 158:1328–1338CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Placzek AT, Scanlan TS (2015) New synthetic routes to thyroid hormone analogs: d6-sobetirome, 3H-sobetirome, and the antagonist NH-3. TetrahedronCrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Placzek AT, Ferrara SJ, Hartley MD, Sanford-Crane HS, Meinig JM, Scanlan TS (2016) Sobetirome prodrug esters with enhanced bloodbrain barrier permeability. Bioorg Med Chem 24:5842–5854CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jordan Devereaux
    • 1
  • Skylar J. Ferrara
    • 1
  • Thomas S. Scanlan
    • 1
  1. 1.Program in Chemical Biology, Department of Physiology & PharmacologyOregon Health & Science UniversityPortlandUSA

Personalised recommendations